As part of the Edison Group’s offering, giving their clients greater exposure to the investor community, Good Call Media was asked to interview the CEO and President of International Life Science company Volition Rx (VNRX) about their financial results and performance in 2016. The company develop simple, easy-to-use blood based cancer tests to accurately diagnose a range of cancers. It was fascinating to learn that one day cancer could be detected as part of a routine blood test. This type of testing is still in its nascent stages but analysts believe the tests have great potential serving an unmet medical need.
Cameron Reynolds said “Volition had a year of remarkable success. We reached a series of significant clinical and operational milestones, enabling the Company’s transition into its commercial phase.”